CodeMap® Compliance Briefing: October 4, 2018
Each year, CMS holds a public meeting, which allows stakeholders to publicly comment on new, revised, and reconsidered codes that will be added to the upcoming Medicare Clinical Laboratory Fee Schedule (CLFS). Primarily, CMS requests comments and advice on how to determine the Medicare reimbursement amounts for these new additions to CLFS. CMS held this year's meeting on June 25, 2018, and posted their preliminary pricing determinations last week. The new codes, 99 in all, include significant changes to the codes and payment amounts for BRCA1 and BRCA2 gene tests for hereditary breast and ovarian cancer. Today, we will discuss these proposed Medicare reimbursement amounts and their potential impact on c....
Sorry, the full document you are trying to access requires an active subscription.
Please login to the left.